Neuroendocrine tumours trials in Germany

In Germany 14 Also abroad 244

14 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 2Taking people
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
Where
Berlin, Düsseldorf, Freiburg im Breisgau, München, Würzburg
Age
12 years and over
People
355 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT04924075 · EU 2023-504853-11-00
Phase 3Taking people
DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
Where
Berlin, Cologne, Dresden, Erlangen, Freiburg im Breisgau, Hamburg, Heidelberg, Mainz, Muenster, Tuebingen, Wuerzburg
Age
18 years and over
People
390 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07544654 · EU 2025-523869-22-00
Phase 2/3Taking people
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
Where
Berlin, Erlangen, Essen, Mainz, Marburg, Tübingen, Würzburg
Age
18 years and over
People
440 worldwide
Run by
Exelixis
See details and how to joinNCT06943755 · EU 2025-521043-20-00
No phaseTaking people
Multicenter Study for External Validation of the TB-NET Score
Where
Erlangen
Age
18 years and over
People
400 worldwide
Run by
Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
See details and how to joinNCT07903532
Phase 1/2Not yet taking people in Germany
DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers
Where
Mainz, Stuttgart
Age
18 years and over
People
60 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07707895 · EU 2026-525634-27-00
Phase 3Taking people
A clinical trial of belzutifan and other treatments in people with solid tumors or von Hippel-Lindau (VHL)-related tumors (MK-6482-043)
Where
Magdeburg
Age
18 years and over
People
134 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to join2025-524160-38-00 · EU 2025-524160-38-00
No phaseTaking people
Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior Treatment
Where
Aschaffenburg, Berlin, Bonn, Bremen, Chemnitz, Cologne, Dresden, Erlangen, Essen, Frankfurt, Frankfurt am Main, Freiburg im Breisgau, Giesen, Goettigen, Hamburg, Heidelberg, Kiel, Leer, Leipzig, Lübeck, Ludwigsburg, Mainz, Marburg, Minden, Mülheim, München, Münster, Osnabrück, Saarbrücken, Tübingen, Westerstede, Würzburg
Age
18 years and over
People
150 worldwide
Run by
Ipsen
See details and how to joinNCT07314164
Phase 1Taking people
Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
Where
Essen, Munich
Age
18 years to 100 years
People
116 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07006727 · EU 2024-519111-34-00
Phase 3Taking people
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
Where
Erlangen, Essen, Munich
Age
12 years to 100 years
People
240 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT06784752 · EU 2024-518325-15-00
Phase 2Not yet taking people in Germany
A Trial for the Treatment of Advanced Large-Cell Neuroendocrine Cancer of the Lung
Where
Berlin, Dresden, Essen, Frankfurt Am Main, Gauting, Grosshansdorf, Heidelberg, Hemer, Mainz, Oldenburg, Stuttgart
Age
18 years and over
People
75
Run by
Technische Universität Dresden
See details and how to joinNCT07561645 · EU 2025-524345-28-00
Phase 3Taking people
Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide versus Durvalumab, Carboplatin, and Etoposide in First-Line ES-SCLC (DeLLphi-312)
Where
Chemnitz, Cologne, Dresden, Essen, Frankfurt am Main, Gauting, Grosshansdorf, Kiel, Luebeck, Wuerzburg
Age
18 years and over
People
156 worldwide
Run by
Amgen Inc.
See details and how to join2024-520050-38-00 · EU 2024-520050-38-00
Phase 2Taking people
DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
Where
Berlin, Dresden, Erlangen, Gauting, Grosshansdorf, Heidelberg, Mainz
Age
18 years and over
People
204 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT05882058 · EU 2023-504247-13-00
No phaseTaking people
Risk Factors for Neuroendocrine Neoplasms
Where
Nuremberg
People
14,250
Run by
Bavarian Cancer Registry
See details and how to joinNCT06282016
Phase 2Not yet taking people in Germany
Hyperthermia Enhanced Re-irradiation of Loco-regional Recurrent Tumors
Where
Berlin
Age
18 years and over
People
110
Run by
Charite University, Berlin, Germany
See details and how to joinNCT04889742